

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT: BaMaung, et al.

Express Mail Label No.: EV314261857US

SERIAL NO.: (not yet assigned)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service as Express Mail Post Office to Addressee Service under 37 C.F.R. 1.10 addressed to:

FILED: August 6, 2003

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

FOR: 3-AMINO-2-HYDROXYALKANOIC  
ACIDS AND THEIR PRODRUGS

Date of Deposit: August 6, 2003

EXAMINER: (not yet assigned)

Tanya Parent 8/6/03

GROUP ART UNIT: (not yet assigned)

Tanya Parent Date

CASE NO.: 6958.US.02

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. Applicants respectfully petition and request that the Examiner consider the listed documents and evidence such consideration by making appropriate notations on the attached form. Copies of the listed documents are attached.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Commissioner is authorized to charge our Deposit Account any additional fees (or credit any over payments) that may be required under 37 C.F.R. §§ 1.16 and 1.17 in association with this communication for which full payment has not been tendered.



\* 2 3 4 9 2 \*

23492

ABBOTT LABORATORIES  
Telephone: (847) 937-0042  
Facsimile: (847) 938-2623

Respectfully submitted,  
BaMaung, et al.

Gregory W. Steele  
Gregory W. Steele  
Registration No. 33,796  
Attorney for Applicants

## Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 6958.US.02	SERIAL NO. (not yet assigned)
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)		APPLICANT(S) N. BaMaung, et al.	
		FILING DATE August 6, 2003	GROUP (not yet assigned)
(37 CFR 1.98 (b))			

## U.S.PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
A1	2002-0002152	01/03/02	Craig et al.			

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS-LATION YES NO
B1	99/57098	11.11.99	WO			

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C1	Griffith et al., "Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin", Chemistry and Biology 4(6):461-471 (1997)
C2	Sin et al., "The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2", Proc. Natl. Acad. Sci. USA 94:6099-6103 (1997)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 6958.US.02	SERIAL NO. (not yet assigned)
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)		APPLICANT(S) N. BaMaung, et al.	
		FILING DATE August 6, 2003	GROUP (not yet assigned)
(37 CFR 1.98 (b))			

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
	A1	2002-0002152	01/03/02	Craig et al.			

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS-LATION YES NO
	B1	99/57098	11.11.99	WO			

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C1	Griffith et al., "Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin", Chemistry and Biology 4(6):461-471 (1997)
C2	Sin et al., "The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2", Proc. Natl. Acad. Sci. USA 94:6099-6103 (1997)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.